{"id":"glp-1-ras","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"10–20","effect":"Constipation"},{"rate":"5–15","effect":"Abdominal pain"},{"rate":"5–10","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1240772","moleculeType":"Protein","molecularWeight":"3169.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 RAs bind to and activate GLP-1 receptors on pancreatic beta cells, which stimulates glucose-dependent insulin secretion. They simultaneously inhibit glucagon secretion from alpha cells and delay gastric emptying, all of which contribute to improved glycemic control. Additionally, GLP-1 RAs promote satiety and have been shown to reduce body weight and provide cardiovascular benefits in patients with type 2 diabetes.","oneSentence":"GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby reducing blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:46.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management (in some formulations)"}]},"trialDetails":[{"nctId":"NCT07393360","phase":"NA","title":"Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment","status":"RECRUITING","sponsor":"Pharmanutra S.p.a.","startDate":"2025-12-11","conditions":"Obesity & Overweight","enrollment":144},{"nctId":"NCT07437911","phase":"NA","title":"A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs","status":"RECRUITING","sponsor":"Athletic Greens International","startDate":"2026-02","conditions":"Nutrition Intake, Nutrition Status, Gastrointestinal Microbiome","enrollment":120},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07006142","phase":"NA","title":"Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-01","conditions":"Upper Endoscopy, GLP1-R-related Disease","enrollment":150},{"nctId":"NCT07225816","phase":"PHASE1","title":"Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-07","conditions":"Obesity","enrollment":75},{"nctId":"NCT05872022","phase":"","title":"A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2023-07-05","conditions":"Pregnancy, Obesity, Overweight","enrollment":728},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT07224880","phase":"","title":"Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists","status":"RECRUITING","sponsor":"Cytrellis Biosystems, Inc.","startDate":"2025-10-14","conditions":"glp1 Agonist, Gene Expression, Skin Laxity","enrollment":10},{"nctId":"NCT06981936","phase":"PHASE4","title":"This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control","status":"RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2025-05-15","conditions":"Micronutrient Deficiencies","enrollment":150},{"nctId":"NCT07012642","phase":"EARLY_PHASE1","title":"Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema","status":"RECRUITING","sponsor":"Advanced Reconstructive Surgery Alliance","startDate":"2025-04-09","conditions":"Lymphedema","enrollment":110},{"nctId":"NCT06913881","phase":"","title":"Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2010-01-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":92100},{"nctId":"NCT06775093","phase":"NA","title":"Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-03-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":392},{"nctId":"NCT06581120","phase":"","title":"GLP_1 RA Ultrasound Study","status":"ENROLLING_BY_INVITATION","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-07-08","conditions":"Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration","enrollment":100},{"nctId":"NCT06355219","phase":"","title":"Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines","status":"COMPLETED","sponsor":"Ali Aminian","startDate":"2010-01-01","conditions":"Type 2 Diabetes Mellitus, Obesity, Microvascular Disease","enrollment":3932},{"nctId":"NCT06344247","phase":"NA","title":"Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-09-01","conditions":"Obesity, Chronic Kidney Diseases","enrollment":48},{"nctId":"NCT06236672","phase":"","title":"Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2023-02-15","conditions":"Type 2 Diabetes, Chronic Kidney Diseases","enrollment":348},{"nctId":"NCT05946148","phase":"","title":"Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2018-06-01","conditions":"Non-Alcoholic Fatty Liver Disease, Liver Steatosis","enrollment":78},{"nctId":"NCT04876027","phase":"PHASE4","title":"GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2021-05-15","conditions":"Polycystic Ovary Syndrome","enrollment":68},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04287179","phase":"PHASE3","title":"SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-03-09","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04866667","phase":"","title":"Observational Study of ASCVD Risks of Type 2 Diabetes in East China","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2021-05-01","conditions":"Type 2 Diabetes Mellitus, Arteriosclerotic Cardiovascular Disease, Liraglutide","enrollment":800},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1506,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dulaglutide"],"phase":"marketed","status":"active","brandName":"GLP-1 RAs","genericName":"GLP-1 RAs","companyName":"Shanghai 10th People's Hospital","companyId":"shanghai-10th-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby reducing blood glucose levels. Used for Type 2 diabetes mellitus, Obesity or weight management (in some formulations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}